Autonomic nervous system

Tivic Health Partners with the Feinstein Institutes to Advance its Patent-pending, Non-Invasive Cervical Vagus Nerve Stimulation; Begins Optimization of ncVNS for use in Clinical Indications

Retrieved on: 
星期三, 五月 22, 2024
Biotechnology, General Health, Health, Medical Devices, Consumer Electronics, Health Technology, Technology, Clinical Trials, Nervous system, Stroke, Medical research, Post-traumatic stress disorder, Heart, Autonomic nervous system, Depression, Conditional sentence, Autonomic, Migraine, Vagus nerve, Research, Epilepsy, Northwell Health, Cluster headache, Biomarker, Associate, VNS, Brain, Pharmaceutical industry

Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today it has initiated the second phase of its clinical work to advance its novel non-invasive cervical vagus nerve stimulation (“ncVNS”).

Key Points: 
  • Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today it has initiated the second phase of its clinical work to advance its novel non-invasive cervical vagus nerve stimulation (“ncVNS”).
  • The company has entered into a collaboration agreement with The Feinstein Institutes for Medical Research at Northwell Health to optimize its ncVNS device therapy for use in specific clinical indications.
  • Tivic Health will conduct a second 20-person clinical trial in collaboration with Theodoros Zanos, Ph.D., Associate Professor in the Institute of Bioelectronic Medicine and Head of the Neural and Data Science Lab at the Feinstein Institutes.
  • May 2024: Tivic Health Announces Successful Completion of Non-Invasive Vagus Nerve Stimulation Study (VNS); Demonstrates Clinically Effective Biological Changes in the Autonomic, Cardiac, and Central Nervous Systems

ANESSA Launching “ANESSA Sunshine Project” in 12 Asian countries/regions to support children’s holistic well-being

Retrieved on: 
星期二, 五月 14, 2024
Children, University, Primary, Secondary, Education, Other Health, Health, Cosmetics, Preschool, Retail, Genetics, Consumer, Patient, Xeroderma pigmentosum, Parent, Faculty, Beauty, XP, Autonomic nervous system, Life, Personal, World Health Organization, School, Waseda University, WHO, Multimedia, DSM-IV codes

1 suncare brand in Asia*1 from Shiseido, is proud to unveil the ANESSA Sunshine Project, a groundbreaking initiative to promote children’s holistic well-being by safely harnessing the power of the sun.

Key Points: 
  • 1 suncare brand in Asia*1 from Shiseido, is proud to unveil the ANESSA Sunshine Project, a groundbreaking initiative to promote children’s holistic well-being by safely harnessing the power of the sun.
  • The project will begin in Japan and eventually encompass 12 Asian countries/regions where ANESSA products are sold, namely, China, Hong Kong, Indonesia, Japan, Korea, Macau, Malaysia, Philippines, Singapore, Taiwan Thailand, and Vietnam.
  • The goal is to directly reach over 300,000 children cumulatively, including related initiatives, by 2030.
  • ANESSA will continue offering sunscreen products and financial support to patients suffering from XP, an incurable genetic disease that prevents exposure to UV rays.

Tivic Health Announces Successful Completion of Non-Invasive Vagus Nerve Stimulation Study (VNS); Demonstrates Clinically Effective Biological Changes in the Autonomic, Cardiac, and Central Nervous Systems

Retrieved on: 
星期三, 五月 8, 2024
Medical Devices, Health, Biometrics, Health Technology, Clinical Trials, Biotechnology, Migraine, Parasympathetic nervous system, Post-traumatic stress disorder, Autonomic nervous system, Cluster headache, Stroke, Depression, Heart rate, VNS, Patient, Arousal, Conditional sentence, Epilepsy, Medical research, Nervous system, EEG, Clinical trial, Associate, Anxiety, Vagus nerve, Northwell Health

Through this collaboration, Tivic Health has confirmed the effectiveness of its patent-pending non-invasive cervical vagus nerve stimulation (ncVNS) approach, which induces responses in the autonomic, cardiac, and central nervous systems and can be expected to have clinical utility in several major disease areas.

Key Points: 
  • Through this collaboration, Tivic Health has confirmed the effectiveness of its patent-pending non-invasive cervical vagus nerve stimulation (ncVNS) approach, which induces responses in the autonomic, cardiac, and central nervous systems and can be expected to have clinical utility in several major disease areas.
  • Physiological measurements were taken before, during, and after ncVNS treatment to assess the impact on the autonomic nervous system, cardiac function, and brain activity.
  • The trial validated Tivic Health’s novel and proprietary approach to ncVNS using objective measures of the autonomic nervous system, cardiac function, and brain activity.
  • The vagus nerve regulates many organ systems associated with chronic disease and thus modulating activity in this nerve pathway is of significant interest in the medical industry.

Ultrasound Neuromodulation Shows Promise to Treat Pulmonary Hypertension, Feinstein Institutes Research

Retrieved on: 
星期二, 五月 7, 2024
Health, Science, Radiology, Research, Cardiology, Brain, Cancer, Inflammation, Crohn's disease, Biomedical engineering, Cell, Pulmonary hypertension, American Heart Association, Woman, Blood, Vagus nerve stimulation, Autonomic nervous system, Inflammatory Bowel Diseases, Disease, Heart, Vagus nerve, Death, Diabetes, Interface (computing), Neuroscience, MD, PAH, Doctor of Philosophy, GE Research, Constriction, Spleen, VNS, Human, Sensation, Pressure, Circulation Research, Patient, Arthritis, Nervous system, Molecular medicine, Reflex, Medical research, Multimedia, Paralysis, Biomarker, Credit, Orthostatic hypertension, Heart failure, Medical imaging

Bioelectronic medicine scientists at The Feinstein Institutes for Medical Research used noninvasive, splenic focused ultrasound stimulation (sFUS) and found they can reduce inflammation and improve symptoms of pulmonary arterial hypertension (PAH).

Key Points: 
  • Bioelectronic medicine scientists at The Feinstein Institutes for Medical Research used noninvasive, splenic focused ultrasound stimulation (sFUS) and found they can reduce inflammation and improve symptoms of pulmonary arterial hypertension (PAH).
  • View the full release here: https://www.businesswire.com/news/home/20240507538578/en/
    Feinstein Institutes’ Dr. Stavros Zanos is the senior author on the new bioelectronic medicine ultrasound paper.
  • The research adds to the growing scientific evidence of bioelectronic medicine and neuromodulation as an effective therapy to treat diseases with an inflammatory component.
  • At the Feinstein Institutes, medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

Hudson Mind Launches Two-Step Nervous System Treatment to Relieve Anxiety

Retrieved on: 
星期二, 五月 7, 2024
Brain, Digestion, Sleep, SGB, Syndrome, Transcranial magnetic stimulation, Research, Heart rate, Parasympathetic nervous system, Nervous system, Pressure, Autonomic nervous system, Sympathetic nervous system, Irritability, Neuro, Hydrodissection, Anxiety, Vagus nerve, Medical imaging

NEW YORK, May 7, 2024 /PRNewswire/ -- Hudson Mind, an interventional mental health clinic in New York City, launched their specialized Neuro Reset treatment, which drastically reduces symptoms of chronic anxiety.

Key Points: 
  • NEW YORK, May 7, 2024 /PRNewswire/ -- Hudson Mind, an interventional mental health clinic in New York City, launched their specialized Neuro Reset treatment, which drastically reduces symptoms of chronic anxiety.
  • Having administered thousands of SGBs, Hudson founder and Chief Medical Officer Dr. Jonathann Kuo developed the Neuro Reset as a means of boosting support for the total nervous system.
  • "To overcome the ongoing cycle of stress that modern life perpetuates, we have to support the total nervous system.
  • Neuro Reset joins a range of clinically-proven interventions at Hudson Mind, including IV ketamine therapy and Transcranial Magnetic Stimulation.

CND Life Sciences to Highlight Momentum of Skin Biopsy Diagnostic Tool for Parkinson’s Disease and Related Disorders at the American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
星期五, 四月 12, 2024
Medical Devices, Other Health, Health, Science, Research, Neurodegenerative disease, PAF, American Academy, Lewy body, MCI, CND, DLB, NIH, Skin, Autonomic nervous system, Abstract, MD, Artificial intelligence, Colorado Convention Center, Dementia, Tremor, Patient, AAN, Orthostatic hypotension, Neurology, Harvard Medical School, Diagnosis, Emerging, Biomarker, Algorithm

The results are focused on patients with dementia with Lewy bodies (DLB) and mild cognitive impairment (MCI).

Key Points: 
  • The results are focused on patients with dementia with Lewy bodies (DLB) and mild cognitive impairment (MCI).
  • A second abstract being presented describes the utility of the synuclein skin biopsy in the initial diagnosis and evaluation of Parkinsonian disorders in everyday clinical practice.
  • “All of the research that will be presented during AAN supports the groundbreaking diagnostic advances using skin biopsies to detect, quantify, and monitor neurodegenerative disease progression.
  • Details on relevant presentations are as follows:
    Essential Tremor with Parkinsonism with Normal Dopamine Transporter Imaging: Majority Have Evidence of Peripheral Synucleinopathy

Research Team Progresses to Final Phase in NIH Competition, Pioneering Autonomic Neuromodulation to Expand Applications for Spinal Stimulation

Retrieved on: 
星期四, 三月 21, 2024
Kessler Institute for Rehabilitation, Research, Blood pressure, Reward, Health, TIM, Applied Physics Laboratory, Reynolds Center, Johns Hopkins, SPARC, Learning, Caregiver, News, Rehabilitation, University, Doctor of Philosophy, MD, Quality of life, NIH, Peripheral, Kessler Foundation, Competition, Tetraplegia, Autonomic nervous system, Mobility, Safety, University of Louisville, Neurostimulation, Self-management, Dysautonomia, Bangladesh Technical Education Board, Select Medical, Common Fund for Commodities, Pharmaceutical industry

EAST HANOVER, N.J., March 21, 2024 /PRNewswire/ -- Marking significant progress towards improving the lives of individuals with spinal cord injuries, Kessler Foundation, University of Louisville, and John Hopkins Applied Physics Laboratory (with the support of Medtronic) have collaboratively won the $1,000,000 prize for Phase 2 of the Neuromod Prize for their project titled, "Neuromodulation of the lumbosacral spinal cord for improvement of autonomic function after spinal cord injury." With this win, the team advances to compete for the Phase 3 prize pool of $5 million.

Key Points: 
  • With this win, the team advances to compete for the Phase 3 prize pool of $5 million.
  • Phase 1 called for innovative therapy concepts and development plans, leading to Phase 2's proof-of-concept studies by the eight selected teams.
  • On February 27, 2024, the NIH announced the four Phase 2 victors, marking a breakthrough moment in neuromodulation research.
  • "Most importantly, what we are learning and sharing about neuromodulation through this Competition will influence new approaches to treating other types of disabling autonomic dysfunction."

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Retrieved on: 
星期一, 十一月 27, 2023
CSF, ATH, Natural history, Neuroimaging, NAA, ASX, MRI, MSA, SHS, Biomarker, Plasma, Disease, Brain, Vanderbilt University Medical Center, Doctor of Philosophy, SAN, MRS, Therapy, Multiple system atrophy, Neuroprotection, AAS, Nerve, AFL, Autonomic nervous system, Patient, Diagnosis, Neuron, Medical imaging

The poster entitled, “Relationship between N-acetylaspartate and neurofilament light chain in multiple system atrophy” was presented by Paula Trujillo Diaz, PhD, Research Assistant Professor, Department of Neurology, Vanderbilt University Medical Center.

Key Points: 
  • The poster entitled, “Relationship between N-acetylaspartate and neurofilament light chain in multiple system atrophy” was presented by Paula Trujillo Diaz, PhD, Research Assistant Professor, Department of Neurology, Vanderbilt University Medical Center.
  • N-acetylaspartate (NAA) is a novel biomarker of neuronal integrity with potential for assessing disease severity, monitoring the course of disease, and evaluating the efficacy of disease modifying therapies in MSA.
  • In the study, the data provided evidence that NAA correlates with levels of neurofilament light chain (NfL) in patients with early MSA.
  • “The data presented at AAS reveals another potentially important biomarker for the evaluation of this rapidly progressive disease with no approved treatment.

New Treatment Restores Sense of Smell in Patients with Long COVID

Retrieved on: 
星期一, 十一月 20, 2023
Jefferson Health, Health, RSNA, Neck, Research, Head, Food, Nose, Patient, Arrhythmia, Headache, Heart rate, Appetite, Stroke, COVID-19, Smell, Phantosmia, Newsroom, Infection, Angina, Autonomic nervous system, Digestion, Ear, Education, Quality of life, Society, Environment, Radiology, Radiation, COVID, Blood pressure, Medical imaging, Pharmaceutical industry, Dentistry, Birth control, Parosmia

Parosmia, a condition where the sense of smell no longer works correctly, is a known symptom of COVID-19.

Key Points: 
  • Parosmia, a condition where the sense of smell no longer works correctly, is a known symptom of COVID-19.
  • While most patients do recover their sense of smell over time, some patients with long COVID continue to have these symptoms for months, or even years, after infection, negatively impacting their appetite for food and their overall quality of life.
  • The distorted sense of smell can also affect smell perception, and some patients may suffer from phantosmia, a condition that causes people to detect smells—foul or pleasant—that aren't in their environment.
  • To assess a possible treatment for patients with long-term post-COVID parosmia, researchers looked at the potential benefits of CT-guided stellate ganglion block.

Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System

Retrieved on: 
星期四, 十一月 16, 2023
SEQUOIA, American Autonomic Society, Autonomic nervous system, OHQ, Orthostatic hypotension, AAS, Patient, University School, Research, Week, Noh, Neurology, Dysautonomia, Pharmaceutical industry, Medical imaging

DUBLIN, Nov. 16, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that a new, anchor-based analysis of ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 34th International Symposium on The Autonomic Nervous System, a meeting of the American Autonomic Society (AAS), taking place November 15-18, 2023, in Rio Grande, Puerto Rico.

Key Points: 
  • DUBLIN, Nov. 16, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that a new, anchor-based analysis of ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 34th International Symposium on The Autonomic Nervous System, a meeting of the American Autonomic Society (AAS), taking place November 15-18, 2023, in Rio Grande, Puerto Rico.
  • Anchor-based analyses help establish thresholds used to interpret the clinical meaningfulness of changes in patient-reported outcomes measures such as the Orthostatic Hypotension Questionnaire (OHQ).
  • This anchor-based analysis model will aid in the interpretation of clinically meaningful changes to the OHSA composite score observed in CYPRESS.
  • Further, establishment of an anchor-based, clinically meaningful change in the OHSA composite primary endpoint will be important for clinicians, regulators, and payors.